Dr. Reddy’s Laboratories Ltd Q1 FY26: Can India’s Generic Giant Keep the Prescription Profits Coming?
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
India’s pharmacy-on-speed-dial just dropped its Q1 FY26 script — revenue up 11%, PAT steady, and USFDA playing peek-a-boo with Form 483. With ₹85.5 billion in revenue and a P/E under 20, Dr. Reddy’s is still prescribing growth without overdosing on drama.
2. Introduction with Hook
Imagine a pharma company that’s part Rambo, part monk — shooting off 400+ generics into global markets while quietly dodging regulatory bullets. That’s Dr. Reddy’s for you. With ₹33,500+ Cr TTM revenue and ₹5,743 Cr PAT, it’s got the precision of a surgeon and the risk appetite of a Formula 1 driver with a lab coat.
11% revenue growth in Q1 FY26
ROCE of 23% and cash flows strong enough to make mutual funds blush
Now, let’s dissect this pill.
3. Business Model (WTF Do They Even Do?)
Dr. Reddy’s is basically that student who not only does the assignment but also corrects the professor’s grammar. It makes:
Generic drugs (cheap but effective — unlike your gym trainer’s diet advice)
APIs (the secret sauces behind the pills)
Biosimilars (big pharma’s bootlegged cousin)
Custom pharma services (freelancing for drug R&D)
All this spread over markets like the US, Europe, Russia, and India. They’re less “local chemist,” more “global prescription overlord.”
